Search - tctmd.com

Displaying 1 - 20 of 35

Sort: Relevancy | Date

Presentation TCT 2025

Unmet Needs in HFrEF: The Clinical Opportunity

Presenter: Stefan Verheye

October 27, 2025

Presentation TCT 2025

Rebirth of Novel Stent Technologies for Coronary PCI

Presenter: Stefan Verheye

October 26, 2025

Presentation TCT 2025

TCT 793: Sex Specific Outcomes of Treating Patients with Refractory Angina with the Coronary Sinus Reducer: One-year outcomes from the REDUCER-I Registry

Presenter: Stefan Verheye

October 26, 2025

Presentation TCT 2023

TCT 617: Plaque Stabilization and Regression: Another Significant Benefit of DynamX Bioadaptor

Presenter: Stefan Verheye

October 25, 2023

Presentation TCT 2023

A Randomized Clinical Trial of a Novel Triple Drug Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus: Six-Month Clinical and Imaging Results of the DESyne BDS Plus Study

Presenter: Stefan Verheye

October 25, 2023

Presentation TCT 2023

DESyne BDS Plus Stent

Presenter: Stefan Verheye

October 24, 2023

Presentation TCT 2023

The Coronary Sinus Reducer

Presenter: Stefan Verheye

October 24, 2023

Presentation TCT 2023

Lithotrispy: A novel approach to calcium fragmentation

Presenter: Stefan Verheye

October 24, 2023

Presentation TCT 2019

Sirolimus-Coated Balloon Therapy: State of Development

Presenter: Stefan Verheye

September 28, 2019

Presentation TCT 2019

DynamX Bioadaptor, an Innovative Device That Adapts to Patients’ Physiology for PCI Treatment of Coronary Artery Disease: 12-Month Clinical and Imaging Results

Presenter: Stefan Verheye

September 27, 2019

Presentation TCT 2019

TCT 45: Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First Cohort Subjects at 12-month Follow-up of the BIOSOLVE-IV Registry

Presenter: Stefan Verheye

September 25, 2019

Presentation EuroPCR 2018

Safety and performance of the resorbable magnesium scaffold, Magmaris in a real world setting - First 200 subjects at 12-month follow-up of the BIOSOLVE-IV registry

Presenter: Stefan Verheye

May 25, 2018

Presentation TCT 2017

Desolve Nx, Cx, and Amity: A Family of Progressively Thinner-Strut PLLA-Based BRS With Novel Properties

Presenter: Bernard R. Chevalier, Corrado Tamburino, Stefan Verheye

October 31, 2017

Presentation TCT 2017

TCT 16: Prospective, Multicenter Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold - Imaging Outcomes and Five-Year Clinical and Imaging Results

Presenter: Stephan Achenbach, Jacques J. Koolen, Stefan Verheye

October 31, 2017

$Special Lecture: Treatment of Refractory Angina - Reducer-1 European Registry and US Approval Trial (With Discussion)$

Presentation TCT 2017

Special Lecture: Treatment of Refractory Angina - Reducer-1 European Registry and US Approval Trial (With Discussion)

Presenter: Philippe Genereux, Simon J. Walsh, Stefan Verheye

October 30, 2017

Presentation TCT 2014

Sirolimus-Eluting Balloon Angioplasty Dilatation System for ISR Indication: The SABRE Trial

Presenter: Todd J. Brinton, Ian T. Meredith, Greg L. Kaluza, Stefan Verheye

September 16, 2014

Presentation TCT 2014

BRS with Clinical Data I DESolve: Differentiating Features and Clinical Update

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Stefan Verheye

September 16, 2014

Presentation TCT 2014

Acute and chronic effects of cryotherapy on atherosclerotic plaque composition in the thoracic aorta of cholesterol-fed rabbits: a potential solution for treatment of plaques

Presenter: Stefan Verheye

September 16, 2014

Presentation TCT 2014

TCT 599: Final Procedural, 30-Day and 6-Month Angiographic, Clinical, and OCT Outcomes from the DIRECT II Trial Using the Svelte Integrated Delivery System with Enzymatic Bioabsobable Sirolimus Coating

Presenter: Marie-Claude Morice, Giulio G. Stefanini, Pedro A. Lemos, Stefan Verheye

September 15, 2014

Presentation TCT 2014

Novolimus-Eluting from a Bioabsorbable Polymer: Latest Update from EXCELLA II

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil, Stefan Verheye

September 15, 2014

Advertisement

Unmet Needs in HFrEF: The Clinical Opportunity

Rebirth of Novel Stent Technologies for Coronary PCI

TCT 793: Sex Specific Outcomes of Treating Patients with Refractory Angina with the Coronary Sinus Reducer: One-year outcomes from the REDUCER-I Registry

TCT 617: Plaque Stabilization and Regression: Another Significant Benefit of DynamX Bioadaptor

A Randomized Clinical Trial of a Novel Triple Drug Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus: Six-Month Clinical and Imaging Results of the DESyne BDS Plus Study

DESyne BDS Plus Stent

The Coronary Sinus Reducer

Lithotrispy: A novel approach to calcium fragmentation

Sirolimus-Coated Balloon Therapy: State of Development

DynamX Bioadaptor, an Innovative Device That Adapts to Patients’ Physiology for PCI Treatment of Coronary Artery Disease: 12-Month Clinical and Imaging Results

TCT 45: Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First Cohort Subjects at 12-month Follow-up of the BIOSOLVE-IV Registry

Safety and performance of the resorbable magnesium scaffold, Magmaris in a real world setting - First 200 subjects at 12-month follow-up of the BIOSOLVE-IV registry

Desolve Nx, Cx, and Amity: A Family of Progressively Thinner-Strut PLLA-Based BRS With Novel Properties

TCT 16: Prospective, Multicenter Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold - Imaging Outcomes and Five-Year Clinical and Imaging Results

Special Lecture: Treatment of Refractory Angina - Reducer-1 European Registry and US Approval Trial (With Discussion)

Sirolimus-Eluting Balloon Angioplasty Dilatation System for ISR Indication: The SABRE Trial

BRS with Clinical Data I DESolve: Differentiating Features and Clinical Update

Acute and chronic effects of cryotherapy on atherosclerotic plaque composition in the thoracic aorta of cholesterol-fed rabbits: a potential solution for treatment of plaques

TCT 599: Final Procedural, 30-Day and 6-Month Angiographic, Clinical, and OCT Outcomes from the DIRECT II Trial Using the Svelte Integrated Delivery System with Enzymatic Bioabsobable Sirolimus Coating

Novolimus-Eluting from a Bioabsorbable Polymer: Latest Update from EXCELLA II

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content